TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
TScan Therapeutics has received clearance from the US FDA for its investigational new drug (IND) applications for T-Plex, TSC-204-A0201, and TSC-204-C0702.
Primary IND for solid tumor program, T-Plex, supports simultaneous use of multiple TCRs to create customized, multiplexed TCR-T cell therapies based on target and HLA expression INDs for. | January 23, 2023